By Adam L. CataldoGSK said on Friday that its vaccine to prevent respiratory-tract disease has been approved for expanded usage in the U.S. by the Food and Drug Administration. Arexvy, which is used to prevent RSV lower respiratory tract disease, can now be given to people ages 50 through 59 who are considered to be at an increased risk of contracting the disease, GSK said. In the U.S., the vaccine is currently approved for those 60 and older. Adults with underlying medical conditions, such as chronic obstructive pulmonary disease, asthma and diabetes are at increased risk from the infection as it can make these conditions worse, GSK said. (END) Dow Jones NewswiresJune 07, 2024 19:36 ET (23:36 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal June 07, 2024 23:48 UTC